DOI: 10.1055/s-00000069

Seminars in Liver Disease

Referenz

Finn RS, Kang YK, Mulcahy M , et al.
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.

Clin Cancer Res 2012;
18 (7) 2090-2098

Bibliographische Angaben herunterladen

Suchen in:
Aufrufen in: